Study of NMS-1116354 in Advanced/Metastatic Solid Tumors
The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced/metastatic solid tumors.
Advanced/Metastatic Solid Tumors
DRUG: NMS-1116354
First cycle dose-limiting toxicities (DLTs) and related maximum tolerated dose(MTD), 3 weeks
Evaluation of pharmacokinetics: plasma concentration at different times after dosing, area under the curve (AUC), maximum plasma concentration (Cmax), time of occurence of Cmax (tmax) and half-life (tÂ½), 6 weeks
The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced/metastatic solid tumors.